Medical Technology · us
A Further Step Toward Assessing Myocardial Infarction at Home: HeartBeam Receives FDA Breakthrough Device Designation
Bringing ECGs to where symptoms occur is the gap in care HeartBeam aims to fill. Breakthrough Device designation accelerates communication on development and review, but following a 134-patient pilot study, a pivotal trial is still needed to validate the use; the current cleared indications do not include myocardial infarction assessment.
When cardiac warning signs appear, access to an ECG before a patient reaches the hospital might help physicians understand the patient's condition earlier. HeartBeam is trying to bring this information into the home setting. On October 5, the company announced that its HeartBeam System, intended to assess suspected myocardial infarction, had received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), advancing the regulatory process for this use, which remains under development.
The portable platform captures the heart's electrical signals from three noncoplanar directions, then uses software to synthesize a 12-lead ECG, with the aim of giving physicians more information to interpret outside the hospital. Here, “3D” refers to the directions from which electrical signals are captured, rather than a three-dimensional image of the heart; the synthesized result is also similar to, rather than identical to, a standard 12-lead ECG. Whether it can support myocardial infarction assessment requires validation for that use.
HeartBeam said the designation was based on evidence including proof-of-concept data presented at the 2025 American Heart Association Scientific Sessions and the ALIGN-ACS pilot study involving 134 patients; RTTNews's report on the same day also mentioned these two sets of evidence. However, the announcement did not provide sensitivity, specificity, or a full breakdown of the participant population. It is therefore not yet possible to determine how accurately the system identifies myocardial infarction, much less infer its performance in routine home use.
Breakthrough Device designation provides opportunities for higher-priority FDA interaction and review; it does not mean that this new use has received marketing authorization. Benzinga's report also characterized it as development progress toward expanded indications. The current cleared indications for the HeartBeam platform and its ECG synthesis software are primarily for healthcare professionals to manually assess certain non-life-threatening arrhythmias. Current labeling explicitly excludes myocardial infarction and myocardial ischemia, and the software does not independently perform cardiac analysis.
The next step will be a multicenter pivotal trial. According to the company's announcement and RTTNews's report, HeartBeam expects to obtain FDA feedback on the trial design in the coming months and anticipates beginning enrollment afterward. If the study is successful, its results will be used to support a future application to expand the indications. This remains a planned pathway, and the announcement has not yet specified the pivotal trial's enrollment size, primary endpoints, or completion date.
Benzinga also reported that HeartBeam has applied to join the FDA's Total Product Life Cycle Advisory Program (TAP), but an application does not mean it has been accepted. The company also said it would provide updates on the ALIGN-ACS data presentation at the TCT conference and progress in the HEADSTART-ACS study. For myocardial infarction assessment at home, the most important evidence ahead is whether the system can reliably provide information for interpretation in the intended patient population and actual use settings; faster regulatory communication still needs to be followed by clinical results.